Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AAA503
- Development stage
- Phase 2
- Lead developer
- Novartis
- Modality
- Alpha Emitters → Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta Emitters → Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptides
- Administration
- Intravenous
01
Overview
AAA503 (also known as NeoB) is a next-generation radiopharmaceutical developed by Advanced Accelerator Applications (a Novartis company). It consists of a DOTA-coupled gastrin-releasing peptide receptor (GRPR) antagonist, NeoBOMB1, labeled with the beta-emitting radioisotope lutetium-177 (177Lu). GRPR is a G-protein coupled receptor that is frequently overexpressed in various solid tumors, including breast cancer, prostate cancer, and gastrointestinal stromal tumors (GIST). Unlike traditional agonists, AAA503 acts as an antagonist, which may offer improved safety and pharmacokinetic profiles by avoiding receptor activation-induced side effects while maintaining high tumor uptake. The drug is designed for peptide receptor radionuclide therapy (PRRT), delivering targeted radiation to destroy cancer cells while sparing healthy tissue.
- Other names
- [177Lu]Lu-NeoB177Lu-NeoBOMB1lutetium Lu 177 neoB
02
Targets
GRPR (Gastrin-releasing peptide receptor)
Beyond the preview
Go deeper on AAA503.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AAA503.